Breast Cancer :: Glaxo’s Tykerb helps breast cancer patients
GlaxoSmithKline (NYSE: GSK) announced positive data from three key studies on its first-in-class, oral small molecule HER2 kinase inhibitor, Tykerb (lapatinib).
GlaxoSmithKline (NYSE: GSK) announced positive data from three key studies on its first-in-class, oral small molecule HER2 kinase inhibitor, Tykerb (lapatinib).
American ginseng provides greater improvements in fatigue and vitality in patients who receive the highest doses tested, compared to lower doses or no treatment, revealed by researchers.
Allos Therapeutics, Inc. (Nasdaq: ALTH) announced the initiation of patient enrollment in a Phase I/IIa open-label, multi-center study of sequential PDX (pralatrexate) and gemcitabine with vitamin B12 and folic acid supplementation in patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) or Hodgkin’s disease.
A blood test that detects proteins commonly released by a growing tumor could one day become a useful tool for monitoring the effectiveness of chemotherapy and radiation treatment in people with advanced throat cancer, according to a study published in the June 1, 2007, issue of Clinical Cancer Research.
New guidelines for the treatment of post-traumatic stress disorder have been accredited by the National Health and Medical Research Council (NHRMC) and are paving the way to more evidence-based treatment of mental health problems.
Massey scientists have discovered a weak link in human digestion that could revolutionise healthy eating and medical treatment for the chronically-ill.
Hospital admissions are up again according to a report released today by the Australian Institute of Health and Welfare (AIHW).
CIGNA HealthCare President David Cordani to lead CIGNA employees in Cancer Challenge Ride; CIGNA to sponsor CIGNA-Calhoun Rider Zone
A new study analyzing men with localized prostate cancer shows that the specialty of the physician they see can influence the type of therapy they ultimately receive.
Despite modest overall improvements in breast cancer survival rates for women with advanced disease over the last two decades, the rates for black women have not improved and the difference in life expectancy between white and black women continues to widen, according to researchers at the University of Texas M. D. Anderson Cancer Center.